OscotecINVESTORSPress Releases Press Releases Explore Oscotec’s latest press releases and corporate news. Latest News Title Media Date Oscotec “Value-Up Targets Achieved Ahead of Schedule… Two Licensing Deals, Return to Profitability”Nov 6, 2026Lee Sang-hyun, CEO of OSCOTEC Inc.: “2.5 billion investment yielded 1.5 trillion in L/O results, proven by new drug”Oct 28, 2026Leclaza-first regimen cuts skin side effects in Korea without losing efficacyOct 25, 2026Oscotec to Participate in BIO USA, Seeking Global Partnerships for Next-Generation PipelinesAug 24, 2026Youngshin Kwak, Head of Oscotec Research Institute: “We Will Compete with Anti-Resistance Cancer Therapy Within 3 Years” [BioUSA]Aug 24, 2026Oscotec surges on 1 trillion won tech transfer deal with US pharmaJun 2, 2026Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor CevidoplenibJun 1, 2026‘Oscotec proves competitiveness in targeting tau protein for Alzheimer’s treatment with tech transfer to Sanofi’Dec 26, 2025Oscotec and ADEL License Alzheimer’s Drug Candidate to Sanofi in KRW 1.5 Trillion DealDec 16, 2025[BIO USA] Oscotec advances ‘chemotherapy resistance novel drug’…“Expanding pipeline with at least two additional assets”Jun 26, 2025Oscotec wins FDA nod for anti-resistance cancer trial, drops oral denfivontinib over safety issuesMay 2, 2025Oscotec to test cevidoplenib as 1st-line ITP drug through investigator-led trialApr 22, 2025 123»
Oscotec “Value-Up Targets Achieved Ahead of Schedule… Two Licensing Deals, Return to Profitability”Nov 6, 2026
Lee Sang-hyun, CEO of OSCOTEC Inc.: “2.5 billion investment yielded 1.5 trillion in L/O results, proven by new drug”Oct 28, 2026
Oscotec to Participate in BIO USA, Seeking Global Partnerships for Next-Generation PipelinesAug 24, 2026
Youngshin Kwak, Head of Oscotec Research Institute: “We Will Compete with Anti-Resistance Cancer Therapy Within 3 Years” [BioUSA]Aug 24, 2026
Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor CevidoplenibJun 1, 2026
‘Oscotec proves competitiveness in targeting tau protein for Alzheimer’s treatment with tech transfer to Sanofi’Dec 26, 2025
[BIO USA] Oscotec advances ‘chemotherapy resistance novel drug’…“Expanding pipeline with at least two additional assets”Jun 26, 2025
Oscotec wins FDA nod for anti-resistance cancer trial, drops oral denfivontinib over safety issuesMay 2, 2025